BiotechTube

MEDI8968 + Saline

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

May 1, 2013 → Oct 1, 2014

NCT ID
NCT01838499

About MEDI8968 + Saline

MEDI8968 + Saline is a phase 2 stage product being developed by AstraZeneca for Hidradenitis Suppurativa. The current trial status is terminated. This product is registered under clinical trial identifier NCT01838499. Target conditions include Hidradenitis Suppurativa.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01838499Phase 2Terminated

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
LutikizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
Lutikizumab + PlaceboAbbViePhase 2
52
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
AnifrolumabAstraZenecaPhase 2
52

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85